Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing
Penn Pharma and Xcelience, LLC today announced that the two companies have entered into a joint venture agreement to provide Capsugel's Xcelodose® precision powder micro-dosing system technology on a global basis.
The book Cancer Risk Assessment (John Wiley & Sons) is now available. The book provides a comprehensive overview of key fundamentals in cancer biology, cancer risk assessment, science policy, testing guidelines, regulatory frameworks, and methods needed to perform cancer risk assessments.
Prodotti Gianni SpA named exclusive distributor for Italy.
Grupo Taper SA named exclusive distributor for the Iberian region.
Please enjoy the June issue of DASGIP Spotlight highlighting three of our latest news on products, applications and business development. We also invite you to get to know Dr Manuel Quirós Asensio, researcher of the Science Institute of Vine and Wine in Logroño, Spain.
Cancer Research Technology (CRT) and Medical Research Council Technology (MRCT) will "swap" medical discoveries to accelerate the translation of early scientific research into patient benefit.
Synergy has recently won a major contract with PepsiCo to provide an outsourced sensory appraisal panel of 24 individuals.
Lekishia White, managing director for Multipharma, Inc. was a featured speaker at the VIBpharma Clinical Trial Supply West Coast 2010 Conference on 2 and 3 June in San Francisco, California.
Kay-Christian Karstadt, executive director GCTS, Multipharma, was a featured expert speaker at the SMI 4th Annual Clinical Trial Logistics Conference. The two-day conference was held in London and addressed concerns and provided attendees with tools for safely and efficiently resolving clinical trials logistical challenges on a global scale.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.